Results for this period
First quarter1 July 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousands of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The main factors were delays in customer acceptance schedules in the Optical business, lower sales and higher selling, general and administrative expenses, mainly research and development costs, in the Life Science and Instrument Development businesses, and lower selling, general and administrative expenses in the Other businesses.
No applicable items
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2026–30 September 2026 |
| Net Sales | 158 Millions of yen (YoY -32.1%) |
| Operating profit | -215 Millions of yen |
| Ordinary income | -220 Millions of yen |
| Profit attributable to owners of the parent | -156 Millions of yen |
| Net income per share | -¥26.46 |
| Equity ratio | End of the current fiscal period 76.9 / End of previous period 79 |
| Total assets | 3,507 Millions of yen |
| Net assets | 2,696 Millions of yen |
| Cash flows from operating activities | 185,134 Thousands of yen |
| Cash flows from investing activities | -15,579 Thousands of yen |
| Cash flows from financing activities | -22,019 Thousands of yen |
| Cash and cash equivalents at end of period | 665,073 Thousands of yen |
| Full-year earnings forecast | Net Sales 1,962 Millions of yen / Operating profit 74 Millions of yen / Ordinary income 106 Millions of yen / Profit attributable to owners of the parent 60 Millions of yen |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | 0 Yen → 0 Yen（0.0%） |
| Segment revenue | Optical business 119,407 Thousands of yen (YoY -37.1%), Life Science and Equipment Development business 6,397 Thousands of yen (YoY -46.3%), Other businesses 32,204 Thousands of yen (YoY +4.9%) |
| Segment profit | Optical business -7,735 Thousands of yen, Life Science and Equipment Development business -45,347 Thousands of yen, Other businesses -30,685 Thousands of yen |
| Depreciation and amortization | 35,338 Thousands of yen |
| Impairment loss | Not applicable |
| Breakdown of extraordinary income (loss) | Extraordinary income No applicable items / Extraordinary loss Loss on retirement of non-current assets 0 Thousands of yen |
| Disclosure regarding the going concern assumption | No applicable items |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 5,905,500 shares |
| Treasury Shares at Period-End | 985 shares |
| Factors Behind Changes in Business Performance | The main factors were delays in customer acceptance schedules in the Optical business, lower sales and higher selling, general and administrative expenses, mainly research and development costs, in the Life Science and Instrument Development businesses, and lower selling, general and administrative expenses in the Other businesses. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Optical business, customer-related delays in acceptance schedules for some projects that had already been shipped meant that the revenue could not be recognized. In the Life Science and Instrument Development businesses, sales fell below the year-earlier quarter, while higher selling, general and administrative expenses, mainly research and development costs, weighed on profit.